FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973306562> ?p ?o ?g. }

• W2973306562 endingPage "115" @default.
• W2973306562 startingPage "108" @default.
• W2973306562 abstract "Purpose [177Lu]DOTATATE prolongs progression free survival (PFS) in metastatic neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled with long duration of therapy and expense suggest need for better selection. We aim to assess whether baseline [68Ga]DOTATATE-PET/CT parameters, and whether response assessment by PET accurately predicts clinical outcome to [177Lu]DOTATATE. Experimental design Retrospective study of patients receiving [177Lu]DOTATATE was conducted. Patients were followed 3-monthly until disease progression. Four [68Ga]DOTATATE-PET parameters (single lesion SUVmax, tumour to spleen and liver SUV ratios, and SUVmax-av using up to five target lesions in multiple organ sites) were determined at baseline and follow-up. The association between these PET parameters either at baseline, or any changes following treatment, and PET response criteria (PERCIST and modified PERCIST) to predict PFS were determined. Patients were followed 3-monthly until disease progression. Response was determined using RECIST 1.1. Baseline SSTR2 expression was assessed and compared with PET parameters. Results 55 patients with metastatic NETs were identified predominantly small bowel (N = 18) and pancreatic (N = 8) in origin. 16 were low grade, 15 intermediate and 3 high grade. Response to PRRT (N = 47): partial response (PR) 28%, stable disease (SD) 60% progressive disease (PD) 13%. Response to PRRT predicted PFS: PR 71.8 months (95%CI: not achieved), SD 29.1 months (95%CI: 15.2–43.1), and PD 9.7 months (95%CI: 0–21.02). Baseline, single lesion SUVmax predicted both response and PFS with SUV cut-off of 13.0 giving high sensitivity and specificity. Tumoural SUVmax correlated with SSTR2 expression, Spearman’s rho – 0.69, p < 0.01. Conclusions Baseline single lesion SUVmax and SUVmax-av predicts response to [177Lu]DOTATATE. Objective response following PRRT defines a subset of patients with markedly improved PFSBaseline SUVmax 13.0 defines a threshold below which patients have poor response to PRRT and worse PFS. SUV threshold analysis should be taken forward into prospective studies." @default.
• W2973306562 created "2019-09-26" @default.
• W2973306562 creator A5004783631 @default.
• W2973306562 creator A5005944632 @default.
• W2973306562 creator A5007167001 @default.
• W2973306562 creator A5017243208 @default.
• W2973306562 creator A5018419311 @default.
• W2973306562 creator A5039046366 @default.
• W2973306562 creator A5057689103 @default.
• W2973306562 creator A5060311534 @default.
• W2973306562 creator A5063926894 @default.
• W2973306562 creator A5080620533 @default.
• W2973306562 creator A5090126935 @default.
• W2973306562 date "2019-12-01" @default.
• W2973306562 modified "2023-10-06" @default.
• W2973306562 title "68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours" @default.
• W2973306562 cites W1495055668 @default.
• W2973306562 cites W1963940642 @default.
• W2973306562 cites W1970027158 @default.
• W2973306562 cites W1970326135 @default.
• W2973306562 cites W1971674693 @default.
• W2973306562 cites W1984398166 @default.
• W2973306562 cites W1986723218 @default.
• W2973306562 cites W2019607817 @default.
• W2973306562 cites W2025583799 @default.
• W2973306562 cites W2043448289 @default.
• W2973306562 cites W2045009715 @default.
• W2973306562 cites W2050083847 @default.
• W2973306562 cites W2050316046 @default.
• W2973306562 cites W2079241416 @default.
• W2973306562 cites W2086804632 @default.
• W2973306562 cites W2109668482 @default.
• W2973306562 cites W2125398839 @default.
• W2973306562 cites W2155263737 @default.
• W2973306562 cites W2162735572 @default.
• W2973306562 cites W2164500609 @default.
• W2973306562 cites W2168021523 @default.
• W2973306562 cites W2296714984 @default.
• W2973306562 cites W2312724636 @default.
• W2973306562 cites W2508175901 @default.
• W2973306562 cites W2573369749 @default.
• W2973306562 cites W2770481394 @default.
• W2973306562 doi "https://doi.org/10.1016/j.radonc.2019.09.003" @default.
• W2973306562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31542317" @default.
• W2973306562 hasPublicationYear "2019" @default.
• W2973306562 type Work @default.
• W2973306562 sameAs 2973306562 @default.
• W2973306562 citedByCount "57" @default.
• W2973306562 countsByYear W29733065622020 @default.
• W2973306562 countsByYear W29733065622021 @default.
• W2973306562 countsByYear W29733065622022 @default.
• W2973306562 countsByYear W29733065622023 @default.
• W2973306562 crossrefType "journal-article" @default.
• W2973306562 hasAuthorship W2973306562A5004783631 @default.
• W2973306562 hasAuthorship W2973306562A5005944632 @default.
• W2973306562 hasAuthorship W2973306562A5007167001 @default.
• W2973306562 hasAuthorship W2973306562A5017243208 @default.
• W2973306562 hasAuthorship W2973306562A5018419311 @default.
• W2973306562 hasAuthorship W2973306562A5039046366 @default.
• W2973306562 hasAuthorship W2973306562A5057689103 @default.
• W2973306562 hasAuthorship W2973306562A5060311534 @default.
• W2973306562 hasAuthorship W2973306562A5063926894 @default.
• W2973306562 hasAuthorship W2973306562A5080620533 @default.
• W2973306562 hasAuthorship W2973306562A5090126935 @default.
• W2973306562 hasConcept C126322002 @default.
• W2973306562 hasConcept C127077266 @default.
• W2973306562 hasConcept C143998085 @default.
• W2973306562 hasConcept C170493617 @default.
• W2973306562 hasConcept C2775842073 @default.
• W2973306562 hasConcept C2778822529 @default.
• W2973306562 hasConcept C2779066768 @default.
• W2973306562 hasConcept C2779134260 @default.
• W2973306562 hasConcept C2779984678 @default.
• W2973306562 hasConcept C2989005 @default.
• W2973306562 hasConcept C2993559085 @default.
• W2973306562 hasConcept C3017732841 @default.
• W2973306562 hasConcept C44249647 @default.
• W2973306562 hasConcept C71924100 @default.
• W2973306562 hasConceptScore W2973306562C126322002 @default.
• W2973306562 hasConceptScore W2973306562C127077266 @default.
• W2973306562 hasConceptScore W2973306562C143998085 @default.
• W2973306562 hasConceptScore W2973306562C170493617 @default.
• W2973306562 hasConceptScore W2973306562C2775842073 @default.
• W2973306562 hasConceptScore W2973306562C2778822529 @default.
• W2973306562 hasConceptScore W2973306562C2779066768 @default.
• W2973306562 hasConceptScore W2973306562C2779134260 @default.
• W2973306562 hasConceptScore W2973306562C2779984678 @default.
• W2973306562 hasConceptScore W2973306562C2989005 @default.
• W2973306562 hasConceptScore W2973306562C2993559085 @default.
• W2973306562 hasConceptScore W2973306562C3017732841 @default.
• W2973306562 hasConceptScore W2973306562C44249647 @default.
• W2973306562 hasConceptScore W2973306562C71924100 @default.
• W2973306562 hasFunder F4320319985 @default.
• W2973306562 hasFunder F4320334626 @default.
• W2973306562 hasLocation W29733065621 @default.
• W2973306562 hasOpenAccess W2973306562 @default.
• W2973306562 hasPrimaryLocation W29733065621 @default.
• W2973306562 hasRelatedWork W2020357816 @default.

• next